Regulatory Roundup for Week of November 12, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup for Week of November 12, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Encouraging Orphan Drugs
by Jill Wechsler

Pharmaceutical companies, scientists, and regulators are championing the development of new treatments for rare diseases as key to spurring biomedical discovery. Experts at an October conference on rare diseases sponsored by the National Organization for Rare Disorders and the Drug Information Association discussed FDASIA provisions that expand FDA staff, guidance, and public outreach to support orphan drug research and approval. John Jenkins, director of the Center for Drug Evaluation and Research (CDER) Office of New Drugs, outlined additional FDASIA policies that provide assistance to sponsors of “breakthrough therapies,” expand accelerated approval of drugs to treat life-threatening conditions, and special incentives for developing treatments for rare pediatric conditions.

Beyond FDA, the National Center for Advancing Translational Sciences at the National Institutes of Health is supporting development of therapeutics for rare and neglected diseases through its drug “repurposing” program plus collaborative research projects. Venture capitalists, moreover, eye more flexible clinical research requirements for orphan drugs as a way for biopharmaceutical companies to gain regulatory approval more quickly and efficiently.

FDA Updates

FDA has provided information on its Enhanced Communication Team created in response to PDUFA V and FDA’s promotion of innovation through interactive communication between the agency and sponsors during drug development.

The following industry guidance documents have been released by FDA:

Generic drug-user fee notice, October 2012: manufacturers will pay approximately $17,500 for FDA’s Office of Generic Drugs to process a backlogged abbreviated new drug application (ANDA). The first manufacturer to reference a drug master file will pay a one-time fee of $21,340. Filing an ANDA will cost $51,520 at time of submission, and about half that amount for a prior approval supplement. Facility fees are due from FDA by mid-January and will be higher for foreign manufacturers.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here